Silo Pharma, Inc.

SILO

US82711P3001

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 25/09/2026 +04			5-day change	1st Jan Change
1.750 ^USD	-1.13%		-0.57%	-65.69%

09-18	Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment	CI
09-09	Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	CI

Top Midday Decliners

Published on 07/10/2026 at 10:07 pm +04

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Silo Pharma, Inc.

09-18	Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment	CI
09-09	Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	CI
08-19	Silo Pharma, Inc. acquired Certain software, technology, domain names, and related intellectual property of Parkview Consulting from Parkview Consulting Ltd for $0.51 million.	CI
08-19	Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment	MT
08-19	Silo Pharma Receives Notice of Allowance for Canadian Patent Application Covering Lead Asset Spc-15 Targeting Ptsd and Other Stress-Induced Psychiatric Disorders	CI
08-14	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
08-14	Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-22	Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15	CI
07-10	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
07-09	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
06-30	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
06-23	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
06-23	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
06-18	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement	MT

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Companyâ€™s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyâ€™s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerâ€™s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimerâ€™s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Employees

Sector

Biotechnology & Medical Research

More about the company